Published in Vaccine on March 13, 2008
New insights on adenovirus as vaccine vectors. Mol Ther (2009) 1.90
Heterosubtypic immunity to influenza A virus: where do we stand? Microbes Infect (2008) 1.88
Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines (2009) 1.83
Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J Immunol (2011) 1.74
Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS One (2010) 1.64
Live attenuated influenza vaccine (LAIV) impacts innate and adaptive immune responses. Vaccine (2011) 1.59
Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance. J Virol (2011) 1.35
Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret. PLoS One (2010) 1.17
Cold-adapted influenza and recombinant adenovirus vaccines induce cross-protective immunity against pH1N1 challenge in mice. PLoS One (2011) 1.06
Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine. PLoS One (2009) 1.04
GM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates. PLoS One (2010) 1.01
Production of adenovirus vectors and their use as a delivery system for influenza vaccines. Expert Opin Biol Ther (2010) 1.01
Conservation and diversity of influenza A H1N1 HLA-restricted T cell epitope candidates for epitope-based vaccines. PLoS One (2010) 0.97
DNA vaccines for targeting bacterial infections. Expert Rev Vaccines (2010) 0.92
Superior neutralizing antibody response and protection in mice vaccinated with heterologous DNA prime and virus like particle boost against HPAI H5N1 virus. PLoS One (2011) 0.92
Advances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccines. Viruses (2012) 0.89
Mucosal immunization with a candidate universal influenza vaccine reduces virus transmission in a mouse model. J Virol (2014) 0.86
Enhanced immune response against HIV-1 induced by a heterologous DNA prime-adenovirus boost vaccination using mannosylated polyethyleneimine as DNA vaccine adjuvant. Int J Nanomedicine (2013) 0.86
Intranasal administration of adeno-associated virus type 12 (AAV12) leads to transduction of the nasal epithelia and can initiate transgene-specific immune response. Mol Ther (2011) 0.85
Antibodies against conserved antigens provide opportunities for reform in influenza vaccine design. Front Immunol (2011) 0.85
Broader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles. PLoS One (2012) 0.84
Robust immunity and heterologous protection against influenza in mice elicited by a novel recombinant NP-M2e fusion protein expressed in E. coli. PLoS One (2012) 0.83
Protective efficacy and immunogenicity of a combinatory DNA vaccine against Influenza A Virus and the Respiratory Syncytial Virus. PLoS One (2013) 0.82
Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice. Virol J (2012) 0.81
Mucosal vaccination with recombinant adenovirus encoding nucleoprotein provides potent protection against influenza virus infection. PLoS One (2013) 0.81
Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice. Clin Vaccine Immunol (2015) 0.80
Progress on adenovirus-vectored universal influenza vaccines. Hum Vaccin Immunother (2015) 0.80
CD46-mediated transduction of a species D adenovirus vaccine improves mucosal vaccine efficacy. Hum Gene Ther (2014) 0.77
Age Dependence of Immunity Induced by a Candidate Universal Influenza Vaccine in Mice. PLoS One (2016) 0.75
Universal or Specific? A Modeling-Based Comparison of Broad-Spectrum Influenza Vaccines against Conventional, Strain-Matched Vaccines. PLoS Comput Biol (2016) 0.75
Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science (2009) 25.61
Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med (2009) 15.02
Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science (2006) 10.04
Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science (2009) 8.61
A two-amino acid change in the hemagglutinin of the 1918 influenza virus abolishes transmission. Science (2007) 8.38
Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J Virol (2005) 7.88
Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature (2006) 6.46
Lack of transmission of H5N1 avian-human reassortant influenza viruses in a ferret model. Proc Natl Acad Sci U S A (2006) 6.35
Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science (2010) 5.13
H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice. PLoS Pathog (2008) 4.79
A single amino acid substitution in 1918 influenza virus hemagglutinin changes receptor binding specificity. J Virol (2005) 4.71
The guinea pig as a transmission model for human influenza viruses. Proc Natl Acad Sci U S A (2006) 4.58
Glycan topology determines human adaptation of avian H5N1 virus hemagglutinin. Nat Biotechnol (2008) 4.37
Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: the role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza. Proc Natl Acad Sci U S A (2002) 4.26
Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proc Natl Acad Sci U S A (2009) 4.12
Role of host cytokine responses in the pathogenesis of avian H5N1 influenza viruses in mice. J Virol (2006) 4.00
Human HA and polymerase subunit PB2 proteins confer transmission of an avian influenza virus through the air. Proc Natl Acad Sci U S A (2009) 3.91
A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature (2004) 3.90
Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature (2008) 3.47
Contemporary North American influenza H7 viruses possess human receptor specificity: Implications for virus transmissibility. Proc Natl Acad Sci U S A (2008) 3.45
DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis (2011) 3.19
Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design. Sci Transl Med (2010) 3.06
pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol (2004) 3.04
Characterization of highly pathogenic H5N1 avian influenza A viruses isolated from South Korea. J Virol (2005) 2.97
Immunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificity. Science (2007) 2.95
Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine (2005) 2.82
Past, present, and possible future human infection with influenza virus A subtype H7. Emerg Infect Dis (2009) 2.80
Pathogenesis and transmission of avian influenza A (H7N9) virus in ferrets and mice. Nature (2013) 2.80
Quantitative biochemical rationale for differences in transmissibility of 1918 pandemic influenza A viruses. Proc Natl Acad Sci U S A (2008) 2.77
Single gene reassortants identify a critical role for PB1, HA, and NA in the high virulence of the 1918 pandemic influenza virus. Proc Natl Acad Sci U S A (2008) 2.72
The ferret as a model organism to study influenza A virus infection. Dis Model Mech (2011) 2.68
Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol (2003) 2.67
Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J Virol (2004) 2.63
A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med (2010) 2.62
Isolation and characterization of avian influenza viruses, including highly pathogenic H5N1, from poultry in live bird markets in Hanoi, Vietnam, in 2001. J Virol (2005) 2.51
Pathogenesis of emerging avian influenza viruses in mammals and the host innate immune response. Immunol Rev (2008) 2.41
Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis (2007) 2.36
Pathogenesis of avian influenza (H7) virus infection in mice and ferrets: enhanced virulence of Eurasian H7N7 viruses isolated from humans. J Virol (2007) 2.30
Effect of receptor binding domain mutations on receptor binding and transmissibility of avian influenza H5N1 viruses. Virology (2011) 2.28
Pause on avian flu transmission research. Science (2012) 2.24
Highly pathogenic avian influenza H5N1 viruses elicit an attenuated type i interferon response in polarized human bronchial epithelial cells. J Virol (2007) 2.23
Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One (2008) 2.16
Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus. J Virol (2008) 2.14
Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature (2013) 2.08
PB1-F2 expression by the 2009 pandemic H1N1 influenza virus has minimal impact on virulence in animal models. J Virol (2010) 2.01
Receptor specificity and transmission of H2N2 subtype viruses isolated from the pandemic of 1957. PLoS One (2010) 1.95
Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic influenza A (H1N1) viruses. J Virol (2009) 1.94
Protection against lethal influenza virus challenge by RNA interference in vivo. Proc Natl Acad Sci U S A (2004) 1.91
DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg Infect Dis (2002) 1.88
A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J Virol (2011) 1.85
Protective immunity to lethal challenge of the 1918 pandemic influenza virus by vaccination. Proc Natl Acad Sci U S A (2006) 1.83
Pathogenesis and transmission of swine origin A(H3N2)v influenza viruses in ferrets. Proc Natl Acad Sci U S A (2012) 1.80
Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine (2005) 1.80
Pathogenesis of pandemic influenza A (H1N1) and triple-reassortant swine influenza A (H1) viruses in mice. J Virol (2010) 1.79
Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J Virol (2005) 1.78
Integration of clinical data, pathology, and cDNA microarrays in influenza virus-infected pigtailed macaques (Macaca nemestrina). J Virol (2004) 1.77
Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J Virol (2009) 1.73
Influenza virus aerosol exposure and analytical system for ferrets. Proc Natl Acad Sci U S A (2011) 1.70
Epitope-specific human influenza antibody repertoires diversify by B cell intraclonal sequence divergence and interclonal convergence. J Immunol (2011) 1.68
Use of animal models to understand the pandemic potential of highly pathogenic avian influenza viruses. Adv Virus Res (2009) 1.67
Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS One (2010) 1.64
TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection. J Immunol (2011) 1.61
H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine (2008) 1.57
MicroRNA expression and virulence in pandemic influenza virus-infected mice. J Virol (2010) 1.54
Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine (2006) 1.51
Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens. J Virol (2005) 1.47
Ocular infection of mice with influenza A (H7) viruses: a site of primary replication and spread to the respiratory tract. J Virol (2009) 1.47
Synthetic viruses: a new opportunity to understand and prevent viral disease. Nat Biotechnol (2009) 1.47
The development of vaccine viruses against pandemic A(H1N1) influenza. Vaccine (2011) 1.44
Transforming growth factor-β: activation by neuraminidase and role in highly pathogenic H5N1 influenza pathogenesis. PLoS Pathog (2010) 1.44
A single base-pair change in 2009 H1N1 hemagglutinin increases human receptor affinity and leads to efficient airborne viral transmission in ferrets. PLoS One (2011) 1.43
Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine (2009) 1.42
Influenza A virus transmission: contributing factors and clinical implications. Expert Rev Mol Med (2010) 1.41
Lethal dissemination of H5N1 influenza virus is associated with dysregulation of inflammation and lipoxin signaling in a mouse model of infection. J Virol (2010) 1.40